BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19443656)

  • 1. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
    Hanley PJ; Cruz CR; Savoldo B; Leen AM; Stanojevic M; Khalil M; Decker W; Molldrem JJ; Liu H; Gee AP; Rooney CM; Heslop HE; Dotti G; Brenner MK; Shpall EJ; Bollard CM
    Blood; 2009 Aug; 114(9):1958-67. PubMed ID: 19443656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.
    Hanley PJ; Lam S; Shpall EJ; Bollard CM
    J Vis Exp; 2012 May; (63):e3627. PubMed ID: 22588077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
    Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
    Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
    Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
    Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
    J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
    Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
    Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes.
    Park KD; Marti L; Kurtzberg J; Szabolcs P
    Blood; 2006 Sep; 108(5):1770-3. PubMed ID: 16675712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection.
    Zandvliet ML; Falkenburg JH; van Liempt E; Veltrop-Duits LA; Lankester AC; Kalpoe JS; Kester MG; van der Steen DM; van Tol MJ; Willemze R; Guchelaar HJ; Schilham MW; Meij P
    Haematologica; 2010 Nov; 95(11):1943-51. PubMed ID: 20562315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.
    Imahashi N; Nishida T; Ito Y; Kawada J; Nakazawa Y; Toji S; Suzuki S; Terakura S; Kato T; Murata M; Naoe T
    Mol Immunol; 2013 Dec; 56(4):399-405. PubMed ID: 23911395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L; Liu X; Wang X; Sun Z; Song XT
    Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
    Gerdemann U; Katari UL; Papadopoulou A; Keirnan JM; Craddock JA; Liu H; Martinez CA; Kennedy-Nasser A; Leung KS; Gottschalk SM; Krance RA; Brenner MK; Rooney CM; Heslop HE; Leen AM
    Mol Ther; 2013 Nov; 21(11):2113-21. PubMed ID: 23783429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
    Leen AM; Myers GD; Sili U; Huls MH; Weiss H; Leung KS; Carrum G; Krance RA; Chang CC; Molldrem JJ; Gee AP; Brenner MK; Heslop HE; Rooney CM; Bollard CM
    Nat Med; 2006 Oct; 12(10):1160-6. PubMed ID: 16998485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.
    Sun Q; Burton RL; Pollok KE; Emanuel DJ; Lucas KG
    Cell Immunol; 1999 Aug; 195(2):81-8. PubMed ID: 10448007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
    J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.
    Gerdemann U; Vera JF; Rooney CM; Leen AM
    J Vis Exp; 2011 May; (51):. PubMed ID: 21654628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
    Micklethwaite KP; Savoldo B; Hanley PJ; Leen AM; Demmler-Harrison GJ; Cooper LJ; Liu H; Gee AP; Shpall EJ; Rooney CM; Heslop HE; Brenner MK; Bollard CM; Dotti G
    Blood; 2010 Apr; 115(13):2695-703. PubMed ID: 20110422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.